P

Purple Biotech Ltd
D

PPBT

0.60010
USD
-0.02
(-3.21%)
مغلق
حجم التداول
1,254
الربح لكل سهم
-1
العائد الربحي
-
P/E
-0
حجم السوق
5,419,172
الأخبار المقالات

العنوان: Purple Biotech Ltd

القطاع: Healthcare
الصناعة: Biotechnology
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.